Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMPOWER: Nicotinamide riboside in patients with Werner syndrome
jRCTs031190141Completed
- Start
- Mar 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of nicotinamide riboside in Werner syndrome (WS) and atherosclerosis. Primary endpoints: Safety at 26 weeks and Safety at 52 weeks. Started Mar 2021; status: completed.
02
Drugs
nicotinamide riboside
03
Conditions
Werner syndrome (WS)atherosclerosis
Beyond the preview
Go deeper on jRCTs031190141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190141.